Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloDREAM: Allogeneic AdMSC in Critical Limb Ischemia
NCT06795620Phase 1Not yet recruiting
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CellReady in critical limb ischemia (CLI), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Evaluation of the tolerance at 6 months. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
CellReady
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT06795620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06795620.